Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.71 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30137405 | 1.00 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL23979390 | 0.93 | CRBN (0.62) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3654727 | 0.91 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3653462 | 0.88 | CRBN (0.74) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL19954315 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL19954319 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL30892106 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3651039 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL21464374 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL3650600 | 0.86 | CRBN (0.71) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385985-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210206743-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11001566-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2021-05-11 | — | — | US | disclosed |
| EP-3404024-B1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200039950-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFORE, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | KANGPU BIOPHARMACEUTICALS, LTD (CN) | 2020-02-06 | — | — | US | disclosed |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-05-03 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492395-B2 | 7-substituted quinazolinone compounds and compositions comprising the same | CELGENE CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2200999-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009075795-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2009-04-09 | — | — | US | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042177-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206743-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | CYP4F11, WEE1, CYP51A1 | CRBN 4188/4885DDB1 4571/4885TNF 142/4885 |
| US-20090093504-A1 | 6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885TNF 4607/4885 |
| US-20180118713-A1 | 6-, 7-, OR 8-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP2D6, CYP2B6 | CRBN 3949/4885DDB1 3263/4885TNF 4607/4885 |
| US-11001566-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | CRBN 4188/4885DDB1 4571/4885TNF 142/4885 |
| US-20200039950-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFORE, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | CYP2F1, CYP2C19, CYP4F3 | CRBN 4087/4885DDB1 3823/4885TNF 64/4885 |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | CRBN 4188/4885DDB1 4571/4885TNF 142/4885 |
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | CRBN 54/4885DDB1 233/4885TNF 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.